S&P 500   3,839.85
DOW   31,117.18
QQQ   322.82
S&P 500   3,839.85
DOW   31,117.18
QQQ   322.82
S&P 500   3,839.85
DOW   31,117.18
QQQ   322.82
S&P 500   3,839.85
DOW   31,117.18
QQQ   322.82
Log in
NASDAQ:NGM

NGM Biopharmaceuticals Stock Forecast, Price & News

$28.25
-0.13 (-0.46 %)
(As of 01/20/2021 11:14 AM ET)
Add
Compare
Today's Range
$28.20
Now: $28.25
$29.03
50-Day Range
$25.70
MA: $29.50
$31.44
52-Week Range
$9.24
Now: $28.25
$32.05
Volume2,574 shs
Average Volume631,450 shs
Market Capitalization$1.95 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.97
NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in Phase 1 clinical trials to decrease levels of a protein implicated in the dry form of AMD. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

MarketRank

Overall MarketRank

1.68 out of 5 stars

Medical Sector

243rd out of 1,928 stocks

Pharmaceutical Preparations Industry

119th out of 774 stocks

Analyst Opinion: 3.6Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NGM
CUSIPN/A
CIKN/A
Phone650 243 5555
Employees186

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$103.54 million
Book Value$4.96 per share

Profitability

Net Income$-42,790,000.00

Miscellaneous

Market Cap$1.95 billion
Next Earnings Date3/16/2021 (Estimated)
OptionableOptionable
$28.25
-0.13 (-0.46 %)
(As of 01/20/2021 11:14 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NGM News and Ratings via Email

Sign-up to receive the latest news and ratings for NGM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NGM Biopharmaceuticals (NASDAQ:NGM) Frequently Asked Questions

How has NGM Biopharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

NGM Biopharmaceuticals' stock was trading at $15.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NGM stock has increased by 86.5% and is now trading at $28.63.
View which stocks have been most impacted by COVID-19
.

Is NGM Biopharmaceuticals a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NGM Biopharmaceuticals in the last year. There are currently 6 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NGM Biopharmaceuticals stock.
View analyst ratings for NGM Biopharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than NGM Biopharmaceuticals?

Wall Street analysts have given NGM Biopharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NGM Biopharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is NGM Biopharmaceuticals' next earnings date?

NGM Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 16th 2021.
View our earnings forecast for NGM Biopharmaceuticals
.

How were NGM Biopharmaceuticals' earnings last quarter?

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) posted its earnings results on Thursday, November, 12th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.04. The company had revenue of $23.48 million for the quarter, compared to analyst estimates of $18.33 million. NGM Biopharmaceuticals had a negative net margin of 91.64% and a negative return on equity of 29.47%.
View NGM Biopharmaceuticals' earnings history
.

What price target have analysts set for NGM?

8 Wall Street analysts have issued 12 month target prices for NGM Biopharmaceuticals' shares. Their forecasts range from $28.00 to $50.00. On average, they anticipate NGM Biopharmaceuticals' stock price to reach $36.50 in the next twelve months. This suggests a possible upside of 27.5% from the stock's current price.
View analysts' price targets for NGM Biopharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of NGM Biopharmaceuticals' key competitors?

Who are NGM Biopharmaceuticals' key executives?

NGM Biopharmaceuticals' management team includes the following people:
  • Mr. William J. Rieflin J.D., Exec. Chairman of Directors (Age 60)
  • Dr. David J. Woodhouse, CEO & Director (Age 50, Pay $615.75k)
  • Dr. Jin-Long Chen, Founder, Chief Scientific Officer & Director (Age 57, Pay $625.75k)
  • Ms. Siobhan Nolan Mangini, CFO and Principal Financial & Accounting Officer (Age 39)
  • Ms. Valerie L. Pierce J.D., Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer (Age 57)
  • Mr. Brian Muma, VP of HR
  • Dr. Hui Tian, Sr. VP of Research
  • Dr. Alex DePaoli, Chief Translational Officer & Sr. VP
  • Dr. Wenyan Shen, Sr. VP of Biologics and CMC
  • Dr. Hsiao Dee Lieu, Chief Medical Officer & Sr. VP (Age 50)

When did NGM Biopharmaceuticals IPO?

(NGM) raised $100 million in an initial public offering on Thursday, April 4th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen served as the underwriters for the IPO.

What is NGM Biopharmaceuticals' stock symbol?

NGM Biopharmaceuticals trades on the NASDAQ under the ticker symbol "NGM."

How do I buy shares of NGM Biopharmaceuticals?

Shares of NGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NGM Biopharmaceuticals' stock price today?

One share of NGM stock can currently be purchased for approximately $28.63.

How big of a company is NGM Biopharmaceuticals?

NGM Biopharmaceuticals has a market capitalization of $1.98 billion and generates $103.54 million in revenue each year. The company earns $-42,790,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. NGM Biopharmaceuticals employs 186 workers across the globe.

What is NGM Biopharmaceuticals' official website?

The official website for NGM Biopharmaceuticals is www.ngmbio.com.

How can I contact NGM Biopharmaceuticals?

NGM Biopharmaceuticals' mailing address is 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650 243 5555 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.